CLRB
HEALTHCARECellectar Biosciences Inc
$3.53+0.35 (+11.01%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CLRB Today?
No stock-specific AI insight has been generated for CLRB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.43$20.59
$3.53
Fundamentals
Market Cap$15M
P/E Ratio—
EPS$-8.35
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding4.2M
CLRB News
20 articles- Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should KnowYahoo Finance·May 7, 2026
- Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström MacroglobulinemiaAdvfn·May 5, 2026
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström MacroglobulinemiaYahoo Finance·May 5, 2026
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 MillionYahoo Finance·May 5, 2026
- Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026Yahoo Finance·Apr 21, 2026
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)Yahoo Finance·Apr 14, 2026
- Cellectar Biosciences, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 4, 2026
- Cellectar (CLRB) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 4, 2026
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate UpdatesYahoo Finance·Mar 4, 2026
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026Yahoo Finance·Feb 25, 2026
- Cellectar Biosciences Expands Global Intellectual Property EstateYahoo Finance·Feb 17, 2026
- Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare ConferenceYahoo Finance·Jan 9, 2026
- Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha TherapiesYahoo Finance·Dec 16, 2025
- Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·Nov 13, 2025
- Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025Yahoo Finance·Nov 6, 2025
- Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade GliomaYahoo Finance·Oct 27, 2025
- Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade GliomaYahoo Finance·Oct 27, 2025
- Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer ResearchYahoo Finance·Oct 14, 2025
- Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 MillionYahoo Finance·Oct 7, 2025
All 20 articles loaded
Price Data
Open$2.65
Previous Close$3.18
Day High$2.81
Day Low$2.62
52 Week High$20.59
52 Week Low$2.43
52-Week Range
$2.43$20.59
$3.53
Fundamentals
Market Cap$15M
P/E Ratio—
EPS$-8.35
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding4.2M
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development and commercialization of drugs for the treatment of cancer. The company is headquartered in Florham Park, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—